- Home
- KWE vs ONVO Comparison
KWE vs ONVO Comparison
Compare KWE & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- ONVO
- Stock Information
- Founded
- KWE 2017
- ONVO 2007
- Country
- KWE Canada
- ONVO United States
- Employees
- KWE N/A
- ONVO N/A
- Industry
- KWE
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KWE
- ONVO Health Care
- Exchange
- KWE Nasdaq
- ONVO Nasdaq
- Market Cap
- KWE 4.5M
- ONVO 5.3M
- IPO Year
- KWE N/A
- ONVO N/A
- Fundamental
- Price
- KWE $0.47
- ONVO $0.33
- Analyst Decision
- KWE
- ONVO
- Analyst Count
- KWE 0
- ONVO 0
- Target Price
- KWE N/A
- ONVO N/A
- AVG Volume (30 Days)
- KWE 1.2M
- ONVO 163.1K
- Earning Date
- KWE 12-30-2024
- ONVO 02-10-2025
- Dividend Yield
- KWE N/A
- ONVO N/A
- EPS Growth
- KWE N/A
- ONVO N/A
- EPS
- KWE N/A
- ONVO N/A
- Revenue
- KWE $1,113,533.00
- ONVO $103,000.00
- Revenue This Year
- KWE N/A
- ONVO $59.08
- Revenue Next Year
- KWE N/A
- ONVO $18.24
- P/E Ratio
- KWE N/A
- ONVO N/A
- Revenue Growth
- KWE 21.86
- ONVO N/A
- 52 Week Low
- KWE $0.43
- ONVO $0.32
- 52 Week High
- KWE $14.90
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- KWE 38.06
- ONVO 41.39
- Support Level
- KWE $0.48
- ONVO $0.33
- Resistance Level
- KWE $0.54
- ONVO $0.37
- Average True Range (ATR)
- KWE 0.05
- ONVO 0.02
- MACD
- KWE -0.01
- ONVO -0.00
- Stochastic Oscillator
- KWE 31.82
- ONVO 16.67
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.